Search results for "Vascular endothelial growth factor A"

showing 10 items of 180 documents

Angioid streak-related choroidal neovascularization treated by intravitreal ranibizumab.

2010

PURPOSE The purpose of this study was to report the visual outcome of intravitreal therapy with ranibizumab of choroidal neovascularization secondary to angioid streaks after 1-year follow-up. METHODS Nine patients (age, 58 +/- 4 years; range, 53-65 years) were treated with off-label intravitreal injections of 0.3 mg ranibizumab. Primary outcomes were best-corrected visual acuity changes (Early Treatment Diabetic Retinopathy Study logarithm of the minimum angle of resolution and letters) and optical coherence tomography macular thickness changes. RESULTS Mean follow-up was 14 months (+/-2; range, 12-18 months). Mean visual acuity was 0.52 logarithm of the minimum angle of resolution and 30 …

MaleVascular Endothelial Growth Factor Amedicine.medical_specialtyVisual acuitygenetic structuresVisual AcuitymonoclonalAngiogenesis InhibitorsAntibodies Monoclonal HumanizedLoading doseChoroidal neovascularization; male; treatment outcome; injections; middle aged; vascular endothelial growth factor a; female; vitreous body; humans; retreatment; visual acuity; angiogenesis inhibitors; aged; angioid streaks; antibodies monoclonalInjectionsNeovascularizationOptical coherence tomographyOphthalmologyRanibizumabMedicineantibodiesHumansANTI-VEGFAgedintravitreal ranibizumabmedicine.diagnostic_testbusiness.industrySettore MED/30 - Malattie Apparato VisivoAntibodies MonoclonalGeneral MedicineDiabetic retinopathyMiddle Agedmedicine.diseaseeye diseasesChoroidal NeovascularizationVitreous BodyOphthalmologyAngioid streaksChoroidal neovascularizationTreatment OutcomeRetreatmentAngioid StreaksFemalemedicine.symptomRanibizumabbusinessAngioid streak-related choroidal neovascularizationmedicine.drugRetina (Philadelphia, Pa.)
researchProduct

Best-corrected visual acuity and retinal thickness are associated with improved cortical visual processing in treated wet AMD patients

2015

Purpose In response to anti-VEGF treatment for wet AMD retinal anatomy and visual acuity is often remedied. In our previous study, we showed that visual evoked potentials (VEP) improve following successful anti-VEGF treatment. The aim of this study was to investigate, how visual acuity and retinal thickness changes are reflected in VEP parameters. Moreover, we wanted to assess the feasibility of VEP as a novel monitoring tool for wet AMD patients. Methods A total of 16 patients and six control subjects were enrolled in this study. Patients received three bevacizumab intravitreal injections. At the beginning of the study and four to 6 weeks after the last injection, the best-corrected visual…

MaleVascular Endothelial Growth Factor Amedicine.medical_specialtyVisual acuitygenetic structuresexudative age-related macular degenerationvisual acuityAngiogenesis InhibitorsVisual systemRetinaVisual processingchemistry.chemical_compoundOphthalmologyMedicineHumansVisual PathwaysProspective Studiesage-related eye diseasesProspective cohort studyAgedVisual CortexBest corrected visual acuityAged 80 and overRetinaoptical coherence tomographybusiness.industryRetinalta3141General MedicineOrgan Sizeeye diseasesta3125BevacizumabOphthalmologymedicine.anatomical_structureVisual cortexchemistryIntravitreal InjectionsWet Macular DegenerationOptometryEvoked Potentials VisualFemalesense organsmedicine.symptomvisual evoked potentialbusinessTomography Optical CoherenceActa Ophthalmologica
researchProduct

Intravitreal bevacizumab plus grid laser photocoagulation or intravitreal bevacizumab or grid laser photocoagulation for diffuse diabetic macular ede…

2013

To evaluate the anatomical and functional outcomes at 24 months in patients with diffuse diabetic macular edema treated with primary intravitreal bevacizumab (IVB) plus grid laser photocoagulation (GLP) or primary IVB alone or GLP alone.Retrospective, interventional, comparative, multicenter study. We included in this analysis 141 eyes of 120 patients with diffuse diabetic macular edema treated with primary IVB alone (Group A), 120 eyes of 94 patients with GLP therapy (Group B), and 157 eyes of 104 patients treated with IVB plus GLP (Group C).In all 3 groups, the authors observed improvement of Early Treatment Diabetic Retinopathy Study best-corrected visual acuity from baseline to 24-month…

MaleVascular Endothelial Growth Factor Amedicine.medical_specialtygenetic structuresDiabetic macular edemaVisual AcuityAngiogenesis InhibitorsAntibodies Monoclonal HumanizedMacular EdemaOphthalmologymedicineHumansIn patientIntravitreal bevacizumabRetrospective StudiesRetinaDiabetic RetinopathyLaser Coagulationbusiness.industryGeneral MedicineMiddle AgedCombined Modality Therapyeye diseasesbody regionsBevacizumabOphthalmologymedicine.anatomical_structureTreatment OutcomeIntravitreal InjectionsFemalesense organsbusinessTomography Optical CoherenceRetina (Philadelphia, Pa.)
researchProduct

Effects of massage on the expression of proangiogenic markers in rat skin

2018

Introduction. Massage is a physiotherapeutic treatment, commonly used in both therapy and restoration of normal body functions. The aim of this work was to determine the effects of skin massage on stimulating the expression of angiogenesis-initiating factors, i.e. VEGF-A, FGF-2 (bFGF) and CD34 and on skin regeneration processes. Material and methods. The study was conducted on 48 Buffalo strain rats, randomly divided into two groups. In the first group (M, the massaged group), massage was applied five times a week for 7 weeks. In the second study group (C, the control group), the massage was omitted. Massage consisted of spiral movements at the plantar surface of skin for 5 min on each rear…

MaleVascular Endothelial Growth Factor AskinHistologyCD34FGF-2massageReal-Time Polymerase Chain Reaction01 natural sciencesVEGF-APathology and Forensic MedicineAndrology03 medical and health sciences0302 clinical medicineDownregulation and upregulationGene expressionMedicineAnimalsHumansRegenerationratCell ProliferationMessenger RNAMassageintegumentary systembiology010405 organic chemistrybusiness.industryRegeneration (biology)General MedicineImmunohistochemistry0104 chemical sciencesRatsqPCRGene Expression Regulation030220 oncology & carcinogenesisKi-67biology.proteinImmunohistochemistryKi-67Fibroblast Growth Factor 2CD34businessBiomarkersIHCFolia Histochemica et Cytobiologica
researchProduct

A novel caryophyllene type sesquiterpene lactone from Asparagus falcatus (Linn.); Structure elucidation and anti-angiogenic activity on HUVECs

2011

Abstract In this study the novel caryophyllene type sesquiterpene lactone (aspfalcolide) has been isolated from the leaves of Asparagus falcatus (Linn.) and characterized by IR, 1D NMR, 2D NMR, EI–MS, HR–ESI–MS and X-ray single crystal diffraction analysis. The aspfalcolide crystallizes in the orthorhombic space group P212121 with a = 6.37360(10), b = 7.6890(2), c = 27.3281(6) A, α = β = γ = 90° and Z = 4. One intermolecular O–H⋯O hydrogen bond enforces these natural molecules to form infinite chains through the crystal. Aspfalcolide was screened for its anti-angiogenic activity in human umbilical vein endothelial cells (HUVECs) and the result showed the remarkable inhibitory effect of aspf…

Models MolecularVascular Endothelial Growth Factor AStereochemistryMolecular ConformationAngiogenesis InhibitorsSesquiterpene lactoneUmbilical veinLactoneschemistry.chemical_compoundCell MovementDrug DiscoveryHuman Umbilical Vein Endothelial CellsHumansta116Cell ProliferationAsparagus falcatusPolycyclic SesquiterpenesPharmacologychemistry.chemical_classificationTube formationbiologyHydrogen bondCaryophylleneOrganic ChemistryGeneral Medicinebiology.organism_classificationchemistryOrthorhombic crystal systemAsparagus PlantSesquiterpenesTwo-dimensional nuclear magnetic resonance spectroscopyEuropean Journal of Medicinal Chemistry
researchProduct

Single nucleotide polymorphisms of the vascular endothelial growth factor gene associated with incidence of oral squamous cell carcinoma

2010

J Oral Pathol Med (2010) 39: 786–792 Background:  Vascular endothelial growth factor (VEGF) plays an important role in promoting angiogenesis and is overexpressed in several malignancies. Polymorphisms of the VEGF gene can alter VEGF protein expression, which may be biologically significant and account for heterogeneity in disease risk and outcome. The aim of this case–control study was to evaluate potential associations between single nucleotide polymorphisms (SNP) of the VEGF gene with susceptibility of oral squamous cell carcinoma (OSCC). Patients and methods:  Five VEGF SNP (−1154 G/A, +405 G/C, +936 C/T, −2578 C/A and −460 C/T) were determined in peripheral blood isolated from 80 patie…

Mouth neoplasmCancer ResearchPathologymedicine.medical_specialtyAngiogenesisSingle-nucleotide polymorphismBiologyPathology and Forensic MedicineVascular endothelial growth factorstomatognathic diseaseschemistry.chemical_compoundVascular endothelial growth factor AOtorhinolaryngologychemistrymedicineCancer researchPeriodonticsBiomarker (medicine)SNPOral SurgeryAlleleJournal of Oral Pathology & Medicine
researchProduct

Targeted Therapies in Hepatocellular Carcinoma

2014

Abstract: The onset of hepatocellular carcinoma (HCC) is related to the development of non-neoplastic liver disease, such as viral infections and cirrhosis. Even though patients with chronic liver diseases undergo clinical surveillance for early diagnosis of HCC, this cancer is often diagnosed in advanced stage. In this case locoregional treatment is not possible and systemic therapies are the best way to control it. Until now sorafenib, a Raf and multi-kinase inhibitor has been the best, choice to treat HCC systemically. It showed a survival benefit in multicenter phase III trials. However the proper patient setting to treat is not well defined, since the results in Child-Pugh B patients a…

NiacinamideVascular Endothelial Growth Factor ACarcinoma HepatocellularSettore MED/06 - Oncologia MedicaCirrhosis hepatocellular carcinoma liver disease targeted therapiesAntineoplastic AgentsBiochemistryDrug DiscoveryAnimalsHumansMolecular Targeted TherapyBiologyProtein Kinase InhibitorsPharmacologyPharmacology. TherapyPhenylurea CompoundsTOR Serine-Threonine KinasesLiver NeoplasmsOrganic ChemistryAntibodies MonoclonalSorafenibdigestive system diseasesErbB ReceptorsChemistryLiverMolecular MedicineCurrent Medicinal Chemistry
researchProduct

Associations between single-nucleotide polymorphisms of the VEGF gene and long-term prognosis of oral squamous cell carcinoma.

2012

Department of Otorhinolaryngology, Johannes Gutenberg-University, Mainz, GermanyINTRODUCTION: Functional polymorphisms (SNPs) ofthe vascular endothelial growth factor (VEGF) are asso-ciated with the incidence of oral squamous cell carcinoma(OSCC). An impact of VEGF-SNPs on prognosis of OSCCpatients seems possible. Therefore, correlations betweenprognostic parameters of OSCC patients and five VEGF-SNPs were determined.MATERIALS AND METHODS: In a retrospective long-term study, in 113 OSCC patients that underwentcurative resections, five VEGF-SNPs ( 1154 G/A,+405 G/C, +936 C/T, 2578 C/A, and 460 C/T) wereanalyzed. Associations between SNPs and prognosis(incidence of local recurrent disease, seco…

OncologyMaleVascular Endothelial Growth Factor ACancer ResearchAdenosinechemistry.chemical_compoundGene FrequencyPolymorphism (computer science)Longitudinal StudiesAged 80 and overIncidence (epidemiology)SmokingNeoplasms Second PrimaryMiddle AgedPrognosisVascular endothelial growth factorSurvival RateCarcinoma Squamous CellPeriodonticsBiomarker (medicine)FemaleMouth NeoplasmsOral SurgeryAdultmedicine.medical_specialtyGuanineGenotypeSingle-nucleotide polymorphismPolymorphism Single NucleotideDisease-Free SurvivalPathology and Forensic MedicineCytosineYoung AdultInternal medicinemedicineCarcinomaHumansSurvival rateAgedNeoplasm StagingRetrospective Studiesbusiness.industryHaplotypemedicine.diseasestomatognathic diseasesOtorhinolaryngologychemistryHaplotypesNeoplasm Recurrence LocalbusinessThymineFollow-Up StudiesJournal of oral pathologymedicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology
researchProduct

Monoclonal antibodies in gastrointestinal cancers

2013

Introduction: Among gastrointestinal cancers, colorectal and gastric neoplasms are the most frequent. The development of new targeted drugs improved the efficacy of systemic therapy in advanced stages of those malignancies. Areas covered: This review highlights the main biological processes implicated in gastrointestinal cancer development and progression, such as angiogenesis and epidermal growth factor receptor (EGFR) signaling pathway. On these bases, anti-EGFR and anti-vascular endothelial growth factor (VEGF) monoclonal antibodies in colorectal and gastric cancer are discussed. Data about further monoclonal antibodies in development are also reported. Expert opinion: The use of monoclo…

OncologyVascular Endothelial Growth Factor AColorectal cancerAngiogenesisSettore MED/06 - Oncologia MedicaClinical BiochemistryPredictive Value of TestAntineoplastic AgentVascular Endothelial Growth Factor A; Animals; Antineoplastic Agents; Receptor Epidermal Growth Factor; Humans; Molecular Targeted Therapy; Predictive Value of Tests; Patient Selection; Antibodies Monoclonal; Genetic Testing; Individualized Medicine; Gastrointestinal Neoplasms; Tumor Markers Biological; Signal TransductionGastricDrug DiscoveryMonoclonalEpidermal growth factor receptorMolecular Targeted TherapyPrecision MedicineTumor MarkersColorectalCancerGastrointestinal NeoplasmsbiologyAntibody; Cancer; Colorectal; Gastric; Monoclonal; Animals; Antibodies Monoclonal; Antineoplastic Agents; Gastrointestinal Neoplasms; Genetic Testing; Humans; Individualized Medicine; Molecular Targeted Therapy; Patient Selection; Predictive Value of Tests; Receptor Epidermal Growth Factor; Signal Transduction; Tumor Markers Biological; Vascular Endothelial Growth Factor A; Pharmacology; Clinical Biochemistry; Drug Discovery3003 Pharmaceutical ScienceAntibodies MonoclonalIndividualized MedicineErbB ReceptorsTumor Markers BiologicalGastrointestinal NeoplasmMonoclonalGastric NeoplasmHumanReceptorSignal Transductionmedicine.medical_specialtymedicine.drug_classAntineoplastic AgentsMonoclonal antibodyAntibodiesPredictive Value of TestsInternal medicinemedicineBiomarkers TumorAnimalsHumansGastrointestinal cancerGenetic TestingAntibodyPharmacologyEpidermal Growth Factorbusiness.industryAnimalDrug Discovery3003 Pharmaceutical SciencePatient SelectionCancermedicine.diseaseBiologicalbiology.proteinReceptor Epidermal Growth Factorbusiness
researchProduct

The prevalent KRAS exon 2 c.35 G > A mutation in metastatic colorectal cancer patients: a biomarker of worse prognosis and potential benefit of bevac…

2015

Bevacizumab-containing chemotherapy differently predict increased efficacy in KRAS exon 2 mutant and wild-type metastatic colorectal cancer (MCRC) patients. Mutant compared to wild-type status did not significantly affect progression-free survival (PFS) and overall survival (OS) in patients fit for first line bevacizumab-containing FIr-B/FOx regimen, and after progression. In patients unfit for intensive regimens, mutant status significantly affected PFS, while not OS. Codon 12 KRAS mutations differentially affect GTPase function, and confer worse clinical behaviour. Prognostic relevance of the prevalent c.35 G. >. A KRAS mutation was retrospectively evaluated. Fit c.35 G. >. A mutant patie…

OncologyVascular Endothelial Growth Factor APathologyKRAS c.35 G>A mutationColorectal cancermedicine.medical_treatmentMutantIntensive regimenColorectal Neoplasmmedicine.disease_causeExonMutation RateAntineoplastic Combined Chemotherapy ProtocolsNeoplasm MetastasisProto-Oncogene ProteinMetastatic colorectal cancerHematologyExonsPrognosisNeoplasm MetastasiBevacizumabTreatment OutcomeOncologyDisease ProgressionBiomarker (medicine)KRASColorectal NeoplasmsHumanmedicine.drugmedicine.medical_specialtyBevacizumabGenotypePrognosiExonAntibodies Monoclonal HumanizedProto-Oncogene Proteins p21(ras)Internal medicineProto-Oncogene ProteinsmedicineHumansChemotherapyAntineoplastic Combined Chemotherapy Protocolbusiness.industryBiomarkerras Proteinmedicine.diseaseRegimenMutationras ProteinsBevacizumab; Biomarker; Intensive regimens; KRAS c.35 G>A mutation; Metastatic colorectal cancer; Antibodies Monoclonal Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers; Colorectal Neoplasms; Disease Progression; Genotype; Humans; Mutation Rate; Neoplasm Metastasis; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Treatment Outcome; Vascular Endothelial Growth Factor A; ras Proteins; Exons; Mutation; Hematology; Oncology; Geriatrics and GerontologyGeriatrics and GerontologybusinessBiomarkers
researchProduct